We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The head of the World Health Organization (WHO) cautioned Monday that no “silver bullet” for the coronavirus may emerge from the flurry of potential vaccines entering phase 3 trials. Read More
Severely ill COVID-19 patients given Relief Therapeutics’ RLF-100 (aviptadil) experienced rapid recovery in just three days, according to the company and its research partner NeuroRx. Read More
Eli Lilly has begun a phase 3 trial of its monoclonal antibody LY-CoV555 for the prevention of COVID-19 in residents and staff at long-term care facilities. Read More
Anthony Fauci, director of NIH’s National Institute of Allergy and Infectious Diseases (NIAID), told the House’s coronavirus subcommittee Friday that he’s still “cautiously optimistic” that a COVID-19 vaccine will be delivered before year’s end. Read More
Pfizer and BioNTech have signed an agreement with Japan’s Ministry of Health to supply the country with 120 million doses of their COVID-19 vaccine. Read More
Merck said it plans to launch two large phase 3 trials of its oral COVID-19 antiviral candidate MK-4482 in September and is also moving ahead with trials of two potential vaccines. Read More
Sanofi and GlaxoSmithKline (GSK) have secured a $2.1 billion U.S. government contract to develop and produce 100 million doses of their COVID-19 vaccine candidate. Read More